ACTIVE_NOT_RECRUITING

Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults

Talk to us

Conditions

Acute Kidney InjuryNGALICUadult

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this research is to collect blood and urine from adult patients admitted to an intensive care unit. This is to assess the performance of the ProNephro AKI (NGAL) assay (lab test) as an aid to identify patients at risk for acute kidney injury.

Official Title

Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults (EPACRA-AKI)

Quick Facts

Study Start:2024-10-28
Study Completion:2026-01-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:ACTIVE_NOT_RECRUITING

Study ID

NCT06652100

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:22 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Vasoactive medication administration
  2. * Mechanical ventilation
  3. * Hypoxemia requiring oxygen support therapy including Bilevel positive airway pressure (BIPAP) and high flow nasal canula
  4. * Mean arterial pressure (MAP) less than 60 (within 12 hrs. of ICU admission only)
  5. * Serum Lactate greater than 2.5 mmol/L
  6. * History of solid organ transplantation, renal transplantation included only if more than 3 months prior
  7. * History of bone marrow transplantation Subject with signed informed consent.
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Locations (Sites)

The University of Alabama
Birmingham, Alabama, 35233
United States
UC Davis
Sacramento, California, 95817
United States
Yale University
New Haven, Connecticut, 06510
United States
University of Chicago
Chicago, Illinois, 60637
United States
Johns Hopkins University
Baltimore, Maryland, 21224
United States
Massachusetts General Hospital
Boston, Massachusetts, 02114
United States
University of Michigan
Ann Arbor, Michigan, 48109
United States
University of New Mexico
Albuquerque, New Mexico, 87131
United States
Columbia University
New York, New York, 10032
United States
Wake Forest University
Winston-Salem, North Carolina, 27109
United States
Cleveland Clinic
Cleveland, Ohio, 44195
United States
Medical University of South Carolina
Charleston, South Carolina, 29425
United States

Collaborators and Investigators

Sponsor: BioPorto Diagnostics

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-10-28
Study Completion Date2026-01-31

Study Record Updates

Study Start Date2024-10-28
Study Completion Date2026-01-31

Terms related to this study

Keywords Provided by Researchers

  • NGAL
  • ICU
  • adult

Additional Relevant MeSH Terms

  • Acute Kidney Injury